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ABSTRACT 
The conversion of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) 
and further oxidized species is catalyzed by the Ten-eleven translocation (TET) 
methylcytosine dioxygenase.  Here we provided a temporal control of 5mC oxidation and 
subsequent remodeling of epigenetic states through a split-TET2 enzyme system in 
mammalian cells. This chemical-inducible epigenome remodeling tool provides a precise 
way to interrogate cellular systems and probe the epigenotype-phenotype relations in 
various biological systems. 
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1. INTRODUCTION
DNA methylation, catalyzed by DNA methyltransferases (DNMTs), is a process 
in which a methyl group is added to the carbon 5 position of cytosine to form 5mC. 5mC 
has been considered as an epigenetic mark that functions in transcriptional repression, X-
chromosome inactivation and transposon silencing in the mammalian genome1. The 
recovery of 5mC to cytosine is a successive process in which Tet-eleven translocation 
(TET) family of methylcytosine dioxygenases catalyze the oxidation of 5mC to 5-
hydroxymethylcytosine (5hmC), 5-formylmethylcytosine (5fC) and 5-
carboxymethylcytosine (5caC)2-4. This process adds an additional layer of previously 
underappreciated epigenetic control over the mammalian genome. 5hmC catalyzed by 
TET proteins has been considered to serve as a rate limiting process of TET-mediated 
DNA demethylation2-4, as well as a reliable epigenetic mark5-8. Evidence shows that DNA 
hydroxymethylation is highly correlated with gene expression and some function 
disorders9-11. However, it is still a challenge to establish the causal relations between 
epigenetic modifications on DNA and the phenotypes, owing to the lack of reliable tools 
to accurately control DNA methylation in genome at temporal and spatial resolution. 
To overcome this challenge, we designed a chemical-inducible epigenome 
remodeling tool (CiDER, Scheme 1) to acquire the precise control of adding or removing 
epigenetic DNA modifications to further control the transcription of genes. Rather than 
TET1 or TET3, the catalytic domain of human TET2 (TET2CD, Figure1) has been 
selected as the 
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subject for a split epigenomic modifier for the following major reasons. First, in 
hematological malignancies10, TET2 is the most frequently mutated gene. Plenty of exome 
sequencing data of cancer patients provide abundant information of sensitive spots that 
need to be avoided through the engineering process12-13. Second, the structure of TET2CD 
in complex with 5mC or 5hmC is the only one that has been determined among TET 
proteins14-15, which provides more rationale to the selection of split sites. Third, there is a 
low complexity region (residues 1481-1843) existing in TET2CD which is possible to be 
replaced by a flexible GS linker without significantly compromising the catalytic activity, 
Scheme 1. Design of a chemical-inducible epigenome remodeling(CiDER) tool based on a split TET2 enzyme. 
FKBP12/FRB heterodimerization or FKBP-F36 V homodimerization modules are fused with two inactive fragments 
of a split TET2CD. Upon the addition of rapamycin, split TET2CD fragments reassemble into a functional 
methylcytosine dioxygenase to catalyze the conversion of 5mC into 5hmC and further oxidized species, thus 
promoting DNA demethylation to remodel the epigenetic landscapes in mammalian cells. Reprinted with permission 
from Engineered Split-TET2 Enzyme for Inducible Epigenetic Remodeling by Minjung Lee, Jia Li, Yi Liang, J. Am. 
Chem. Soc., 2017, 139 (13), pp 4659–4662, http://pubs.acs.org/doi/abs/10.1021%2Fjacs.7b01459 
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and hence it offers a structural malleability of TET2CD and increases the flexibility to 
accommodate the insertion of foreign polypeptide sequences15. The replacement of this 
large fragment of low complexity (~1.2 kb) also helps us to minimize the size of the 
constructs. Then, we set out to test the idea that the two inactive fragments of split 
TET2CD can be restored by a chemically inducible dimerization approach. 
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2. RESULT
2.1 Design and optimization of Split-TET2CD constructs 
To develop a split-TET2CD system, six sites have been selected on a Cys-rich 
region and a double-stranded beta-helix (DSBH) fold (Figure 1a,b). A FK506 binding 
protein 12 (FKBP12) and FKBP rapamycin binding domain(FRB)16-17 separated by a self-
cleaving T2A polypeptide sequence18-19 was inserted between the selected split sites of 
TET2CD or TET2CD with a GS linker instead of the low complexity region.  A mCherry-
tag was added on the C-terminal of the constructs (Figure 1c). 
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Figure 1. An engineered split-TET2 enzyme for inducible DNA hydroxymethylation in mammalian cells. (a) 
Domain architecture of the catalytic domain of TET2 (TET2CD; aa 1129−2002) and positions of selected split 
sites. DSBH, double stranded beta helix. (b) Split sites mapped to the 3D structure of TET2CD (PDB entry: 
4NM6) (c) Diagram of CiDER. The chemical-inducible dimerization modules FRB and FKBP12, along with 
a self-cleaving peptide T2A, was inserted into the catalytic domain of TET2 (TET2CD with deletion of 
residues 1462-1839) at split site 3 (Figure 1). The N-terminal region of TET2CD (TETN) is tagged with an 
Myc tag and a nuclear localization signal (NLS); whereas the C-terminal region of TET2CD (TET-C) is fused 
with mCherry to aid the detection of protein expression. Following the expression of CiDER in mammalian 
cells, the fusion protein will be cleaved into two inactive TET2CD fragments. Upon addition of rapamycin, the 
chemically-inducible heterodimerization of FRB and FKBP12 brings the two complementary fragments of 
TET2CD into close proximity to restore its enzymatic function, thereby catalyzing 5mC oxidation to produce 
5hmC. Reprinted with permission from Engineered Split-TET2 Enzyme for Inducible Epigenetic Remodeling 
by Minjung Lee, Jia Li, Yi Liang, J. Am. Chem. Soc., 2017, 139 (13), pp 4659–4662, 
http://pubs.acs.org/doi/abs/10.1021%2Fjacs.7b01459 
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2.2 5hmC level is increased by CiDER upon rapamycin induction in mammalian 
cells 
Each construct was transfected into human embryonic kidney 293T (HEK293T) 
or Hela cells that both have extremely low basal 5hmC levels. The fusion protein was self-
cleaved into two fragments once transfected into HEK293T cells (Figure 2a).
 Figure 2. 5hmc level increased by CiDER. (a) Western blotting to detect the expression of two split TET2CD 
fragments. The N-terminal domain was detected by the anti-Myc antibody (left; calculated MW = 51.9 kDa) 
whereas the Chalf was immunoblotted against an anti-mCherry monoclonal antibody (right; calculated MW = 64.1
kDa). (b) Screening and optimization of split-TET2CD constructs to achieve chemical-inducible 5hmC generation 
in HEK293T cells. The construct with insertion of FKBP12-T2A-FRB at split site 3 and deletion of the low 
complexity region (Δ1462−1839) stood out as the best candidate (termed “CiDER”, S1). (c) Quantification of 
CiDER-mediated 5hmC production by flow cytometry. HEK293T cells transfected with mCherry (mCh)-tagged 
CiDER or mCh-TET2CD (positive control) were mmunostained with an anti-5hmC primary antibody and an 
FITC-labeled secondary antibody.  (d) Dot-blot assay to quantify rapamycin (200 nM)-induced changes of 5hmC 
levels in genomic DNA purified from HEK293T cells expressing CiDER or TET2CD. A synthetic oligonucleotide 
with a known amount of 5hmC was used as a positive control. The loading control was shown in the bottom panel 
by methylene blue staining of total amounts of input DNA. (e) Representative fluorescent images of 5hmC (green), 
CiDER-mCh (red), and nuclear staining with DAPI (blue) in HEK293T cells before and after rapamycin (200 nM)
treatment. Reprinted with permission from Engineered Split-TET2 Enzyme for Inducible Epigenetic Remodeling 
by Minjung Lee, Jia Li, Yi Liang, J. Am. Chem. Soc., 2017, 139 (13), pp 4659–4662, 
http://pubs.acs.org/doi/abs/10.1021%2Fjacs.7b01459 
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In the presence of rapamycin, the production of 5hmC was increased after 
incubating the enriched fragments with a synthetic 5mC-containing dsDNA oligo in vitro, 
indicating that the two fragments could reconstitute a functional enzyme. We further 
compared global 5hmC levels before and after rapamycin treatment by flow cytometry 
(Figure 2b,c). We identified a split-TET2CD variant (designated as CiDER for chemical-
inducible epigenome remodeling tool) that shows the restoration of enzymatic activity 
through rapamycin induction after screening over 15 constructs. There was almost no 
background activity of CiDER prior to the addition of rapamycin.  The total 5hmC level 
was restored in the cells that expressed intact integrated TET2CD proteins after rapamycin 
induction (Figure 2b,c). We further confirmed the generation of 5hmC by rapamycin 
9 
induction through two additional methods: immunostaining and a more quantitative dot-
blot assay that measures the total amounts of 5hmC in the whole cell population. It was 
confirmed by both methods that rapamycin elicited robust production of 5hmC in CiDER-
expressing HEK293T cells (Figure 2d,e). 
2.3 Reversibility of CiDER triggered 5hmC raise 
To detect the reversibility of CiDER, we monitored rapamycin-induced 5hmC 
level at different time points. The result showed that 5hmC level reached a maximum in 
about 48 hours with rapamycin treatment. The 5hmC level returned to its basal level in 
about 3 days after the withdrawal of rapamycin, indicating the constant dilution of 5hmC 
level after multiple rounds of cell division. By contrast, the 5hmC level in the group with 
intact TET2CD remained at high level regardless of whether rapamycin was added or 
removed. (Figure 3). 
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Figure 3. Time course of rapamycin (200 nM)-induced production of 5hmC in HEK293T cells 
expressing CiDER or TET2CD (as positive control). Rapamycin was washed away 48 h after 
incubation with cells. Reprinted with permission from Engineered Split-TET2 Enzyme for 
Inducible Epigenetic Remodeling by Minjung Lee, Jia Li, Yi Liang, J. Am. Chem. Soc., 2017, 
139 (13), pp 4659–4662, http://pubs.acs.org/doi/abs/10.1021%2Fjacs.7b01459 
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3. DISCUSSION 
 
To further improve CiDER system to achieve the spatial control of 5hmC level, 
we plan to fuse it with a catalytically inactive Cas9 or its orthologues which offer the 
possibility of loci-specific targeting of DNA demethylation in genome. It’s quite possible 
that the loci-specific CiDER system could become a powerful tool for interrogating, 
perturbing and engineering cellular system without altering the genetic code. as well as 
reprogramming cell fate and disease intervention. 
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4. METHODS 
 
4.1 Cell culture and plasmid transfection 
HeLa and human embryonic kidney HEK293T cell lines from the American Type 
Culture Collection (ATCC) were cultured in Dulbecco's modified Eagle's medium 
(DMEM, Sigma-Aldrich), supplemented with 10% heat-inactivated fetal bovine serum, 
100 U/ml penicillin/ streptomycin at 37 °C with 5% CO2. Transfection was performed by 
using lipofectamine 3000 (Life Technologies) following the manufacturer’s 
recommended protocol. A total of 200-500 ng DNA was used for each well of a 24-well 
plate. 200 nM rapamycin or AP1903 (Sigma-Aldrich) was applied to the cells. The culture 
media were replaced every 24 h with fresh media containing 200nM rapamycin or AP-
1903. 
4.2 5hmC immunofluorescence staining and imaging 
HeLa cells (4 x 105) were plated on sterile coverslips in 24-well plates. After 24-
48 hours of rapamycin treatment, cells were fixed with 4% paraformaldehyde in PBS for 
15 min and permeabilized with 0.2% Triton X-100 in PBS for 30 min at room temperature. 
Next, DNAs were denatured with 3N HCl at room temperature for 15 min and neutralized 
with 100 mM Tris-HCl buffer (pH 8.0) for 10 min. After extensive washing with PBS, 
cells were blocked with 1% BSA for 30 min, and then incubated with rabbit anti-5-hmC 
polyclonal antibody (diluted at 1:500, Active Motif) for 2 hours at room temperature. After 
washing with PBS (3 times; 15 min each), FITC-conjugated anti-rabbit IgG (Sigma-
Aldrich) was added to the cells and incubated for 1 hour. After thoroughly washing with 
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PBS, 250 ng/ml of 4’,6-diamidino-2-phenylindole (DAPI) was added to the fixed cells 
and then mounted the slides for confocal imaging. The fluorescent images were acquired 
by using a Nikon A1R+ confocal imaging system equipped with multiple laser sources 
(405/488/561/640 nm). 488 nm laser (green) was used to obtain 5hmC staining signals. 
561-nm laser was used to detect mCherry for protein localization. The NISElements 
software was used for image analysis. The averaged FITC intensity in the nuclei of 
mCherry-positive cells were collected and analyzed. The data was plotted using the Prism 
5 software. Images in Figure S1c were acquired using the automated high-content confocal 
imaging system (IN CELL Analyzer, GE Healthcare).  
4.3 Flow cytometry 
Cells were re-suspended in FACS buffer (PBS with 1% BSA, 2 mM EDTA) and 
incubated with Fc blocker for 10 min on ice. After washing with FACS buffer, cells were 
fixed and permeabilized using the Cell Fixation/permeabilization kit from BD 
Biosciences. DNA were denatured by 2N HCl and neutralized by 10 mM Tris-HCl (pH 
8.0) for 20 min. Next, anti-5hmC antibody (Active Motif, 1:200) and FITC conjugated 
goat anti-rabbit secondary antibody (at a dilution of 1:200; Thermo Fisher Scientific) were 
used for 5hmC staining. Flow cytometry analysis was performed using LSRII (BD 
Biosciences) and data were analyzed by using the FlowJo software. 
4.4 A dot-blot assay to quantify genomic 5hmC and 5mC 
Purified genomic DNA was denatured in 0.4 M NaOH, 10 mM EDTA at 95 °C for 
10 min, followed by neutralization with ice-cold 2 M ammonium acetate (pH 7.0). Two-
fold serial dilutions of the denatured DNA samples were spotted on a nitrocellulose 
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membrane in an assembled Bio-Dot apparatus (Bio-Rad) according to the manufacturer’s 
instructions. A synthetic oligonucleotide with a known amount of 5hmC was used as 
standard. The membrane was washed with 2xSSC buffer, air-dried and vacuum-baked at 
80°C for 2 h. The dried membrane was blocked with 5% non-fat milk for 1 hour and 
incubated with an anti-5hmC antibody (1:5000, Active Motif) for 1 hour at 4°C, followed 
by incubation with horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody 
(1:10,000; Sigma). The membrane was visualized by West-Q Pico Dura ECL Solution 
(GenDEPOT). To ensure equal loading of total DNA on the membrane, the same blot was 
stained with 0.02% methylene blue in 0.3 M sodium acetate (pH 5.2) to visualize the total 
amounts of loaded DNA samples. 
4.5 Western blotting 
Cells were lysed with RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1% 
Triton X-100, 0.5% sodium deoxycholate and 0.1% SDS) supplemented with protease 
inhibitor cocktail (GenDEPOT), and incubated on ice for 20 min. Cell debris was removed 
by centrifuging at 30,000 x g for 10 min at 4°C. The protein concentration was measured 
by a Pierce BCA protein assay kit (Thermo Fisher Scientific). Samples were mixed with 
SDS sample buffer at 95°C for 10 min. Whole cell lysates were resolved on 10% or 4-
12% gradient SDS-PAGE and transferred onto nitrocellulose membranes. Proteins were 
detected by immunoblotting in TBST (150 mM NaCl, 10 mM Tris-Cl, pH 8.0, 0.5% 
Tween-20) containing 5% low-fat milk followed by incubation with anti-Myc (GeneTex, 
1:10,000), anti-mCherry (GeneTex , 1:3,000) or anti-GAPDH (Sigma, 1:10,000) at RT for 
1 hr. Then the membrane was incubated with HRP-conjugated secondary antibodies (goat 
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anti-mouse IgG HRP, Sigma) and proteins were detected by using the West-Q Pico Dura 
ECL kit (GenDEPOT). 
4.6 Pull-down experiments and functional reconstitution in vitro 
Myc-CiDER-mCherry encoding the split CiDER (N-terminal half tagged with 
Myc and C-half fused with mCherry) was transfected into HEK293T cells by using 
Lipofectamine 3000 (Life Technologies). 48 h post-transfection, 1X107 cells were lysed 
in a RIPA lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1% Triton X-100, 0.1% 
sodium deoxycholate and 0.05% SDS) supplemented with protease inhibitor cocktail 
(GenDEPOT) and incubated on ice for 20 min. Cell debris was removed by centrifuging 
at 18,000x g for 10 min at 4°C. Cell lysates were incubated with anti-Myc antibody 
(ab1253, Abcam) and/or a rabbit polyclonal anti-mCherry antibody (ab167453, Abcam) 
for 4 hours at 4°C followed by incubation with precleared protein A/G beads (30 ul) 
overnight at 4°C. Protein/beads mixtures were washed with 50 mM HEPES (pH 8.0) 
containing 50 mM NaCl for 5 times. Then we mixed the immunoprecipitated TET2CD, 
N-half or both CiDER fragments with substrate (a double-stranded 5mC containing DNA 
oligos as we used in an earlier study) in a reaction buffer (50 mM HEPES (pH 8.0), 50 mM 
NaCl, 1 mM α-ketoglutarate, 3.7 μM ammonium iron (II) sulfate hexahydrate, 0.1 mg ml-
1 BSA, 1 mM ATP) at 37°C for 30 min. EDTA (11 mM) was then added to quench the 
reaction. DNA and protein mixtures were eluted with 50 mM HEPES (pH 8.0) containing 
200 mM NaCl, 0.2% SDS with incubation at 95°C for 10 min. DNA fragments were 
further purified by MicroElute Cycle-Pure Kit (Omega). 5hmC level was measured by the 
dot-blot assay as described above. 
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5. CONCLUSION 
 
In summary, we engineered split-TET2CD fragments based on the 
TET2CD/5hmC crystal structure to restrict its function temporarily, then employed the 
rapamycin triggered protein dimerization widget to restore the catalytic function of 
TET2CD to convert 5mC to 5hmC. Together, it is CiDER that offers a temporal and 
reversible control of 5hmC level in mammalian cells. 
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APPENDIX 
 
Figure A1: 
CiDER: Myc-NLS-T2SN-linker-FRB-T2A-FKBP12-linker-T2SC-linker-mCherry 
(797 residues without mCherry tag; 1047 residues total)  
 
MEQKLISEEDLKRPAATKKAGQAKKKKGGSASGGSDFPSCRCVEQIIEKDEGPFYTHLG
AGPNVAAIREIMEERFGQKGKAIRIERVIYTGKEGKSSQGCPIAKWVVRRSSSEEKLLC
LVRERAGHTCEAAVIVILILVWEGIPLSLADKLYSELTETLRKYGTLTNRRCALNEERT
CACQGLDPETCGASFSFGCSWSMYYNGCKFARSKIPRKFKLLGDDPKEEEKLESHLQNL
STLMAPTYKKLAPDAYNNQIEYEHRAPECRLGLKEGRPFSGVTACLDFCAHAHRDLHNM
QGAPGGGGSGGGGSGGGGSILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMER
GPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKGSGEGR
GSLLTCGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRN
KPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVE
LLKLEGSGSGSGSGSGSPGNGSTLVCTLTREDNREFGGKPEDEQLHVLPLYKVSDVDEF
GSVEAQEEKKRSGAIQVLSSFRRKVRMLAEPVKPGKKLLPGLGAEDNDEVWSDSEQSFL
DPDIGGVAVAPTHGSILIECAKRELHATTPLKNPNRNHPTRISLVFYQHKSMNEPKHGL
ALWEAKMAEKAREKEEECEKYGPDYVPQKSHGKKVKREPAEPHETSEPTYLRFIKSLAE
RTMSVTTDSTVTTSPYAFTRVTGPYNRYIGTGSGSGSGSGSGSMVSKGEEDNMAIIKEF
MRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSK
AYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNF
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PSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQ
LPGAYNVNIKLDITSHNEDYTIVEQY  
ERAEGRHSTGGMDELYK* 
 
 
Annotation: 
c-myc tag 
NLS 
FRB 
T2A: self-cleaving 2A peptide 
FKBP1A 
mCherry 
T2S: engineered minimal TET2 C+D domain composed of two components 
(T2SN, 1129-1430; T2SC, 1431-2002/ Δ1463-1838) 
 
ATGGAACAAAAACTTATTTCTGAAGAAGATCTGAAAAGGCCGGCGGCCACGAAAAAGGC
CGGCCAGGCAAAAAAGAAAAAGGGAGGTTCCGCTAGCGGAGGTTCGGATTTCCCATCT
TGCAGATGTGTAGAGCAAATTATTGAAAAAGATGAAGGTCCTTTTTATACCCATCTAGG
AGCAGGTCCTAATGTGGCAGCTATTAGAGAAATCATGGAAGAAAGGTTTGGACAGAAGG
GTAAAGCTATTAGGATTGAAAGAGTCATCTATACTGGTAAAGAAGGCAAAAGTTCTCAG
GGATGTCCTATTGCTAAGTGGGTGGTTCGCAGAAGCAGCAGTGAAGAGAAGCTACTGTG
TTTGGTGCGGGAGCGAGCTGGCCACACCTGTGAGGCTGCAGTGATTGTGATTCTCATCC
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TGGTGTGGGAAGGAATCCCGCTGTCTCTGGCTGACAAACTCTACTCGGAGCTTACCGAG
ACGCTGAGGAAATACGGCACGCTCACCAATCGCCGGTGTGCCTTGAATGAAGAGAGAAC
TTGCGCCTGTCAGGGGCTGGATCCAGAAACCTGTGGTGCCTCCTTCTCTTTTGGTTGTT
CATGGAGCATGTACTACAATGGATGTAAGTTTGCCAGAAGCAAGATCCCAAGGAAGTTT
AAGCTGCTTGGGGATGACCCAAAAGAGGAAGAGAAACTGGAGTCTCATTTGCAAAACCT
GTCCACTCTTATGGCACCAACATATAAGAAACTTGCACCTGATGCATATAATAATCAGA
TTGAATATGAACACAGAGCACCAGAGTGCCGTCTGGGTCTGAAGGAAGGCCGTCCATTC
TCAGGGGTCACTGCATGTTTGGACTTCTGTGCTCATGCCCACAGAGACTTGCACAACAT
GCAGGGCGCGCCgGGAGGTGGTGGCAGCGGTGGAGGAGGTTCTGGGGGCGGTGGCTCAA
TTTTATGGCATGAGATGTGGCATGAGGGTTTGGAAGAGGCATCTAGATTGTATTTCGGT
GAAAGAAATGTCAAGGGAATGTTCGAAGTTTTAGAACCGTTGCACGCTATGATGGAGAG
AGGTCCACAGACTCTAAAGGAGACTTCCTTCAACCAAGCTTATGGAAGGGACCTAATGG
AGGCTCAAGAATGGTGTAGAAAATACATGAAAAGTGGAAATGTAAAGGACCTTACACAA
GCTTGGGATCTCTACTACCATGTTTTTAGGAGAATATCTAAAGGAAGTGGTGAGGGTAG
GGGAAGTTTATTAACCTGTGGGGATGTTGAAGAAAATCCAGGTCCTATGGGCGTACAAG
TTGAAACTATCAGCCCTGGGGACGGCAGAACCTTTCCGAAGAGGGGACAGACATGTGTT
GTTCACTATACTGGAATGTTGGAAGATGGTAAGAAGTTCGATAGCAGCAGAGATAGGAA
TAAACCATTTAAATTCATGCTTGGCAAGCAAGAAGTGATTAGGGGTTGGGAAGAAGGTG
TCGCTCAAATGAGTGTAGGTCAGAGGGCTAAGTTAACAATTAGTCCTGATTATGCTTAT
GGCGCTACAGGTCATCCAGGAATCATTCCCCCACATGCTACTCTTGTTTTCGACGTTGA
ATTGCTCAAGCTTGAAGGATCAGGTTCTGGATCTGGTTCAGGATCAGGCTCACCCGGGA
ATGGCAGCACATTGGTATGCACTCTCACTAGAGAAGACAATCGAGAATTTGGAGGAAAA
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CCTGAGGATGAGCAGCTTCACGTTCTGCCTTTATACAAAGTCTCTGACGTGGATGAGTT
TGGGAGTGTGGAAGCTCAGGAGGAGAAAAAACGGAGTGGTGCCATTCAGGTACTGAGTT
CTTTTCGGCGAAAAGTCAGGATGTTAGCAGAGCCAGTCAAGCCCGGGAAGAAGCTTCTT
CCCGGGCTTGGTGCAGAGGACAACGATGAGGTCTGGTCAGACAGCGAGCAGAGCTTTCT
GGATCCTGACATTGGGGGAGTGGCCGTGGCTCCAACTCATGGGTCAATTCTCATTGAGT
GTGCAAAGCGTGAGCTGCATGCCACAACCCCTTTAAAGAATCCCAATAGGAATCACCCC
ACCAGGATCTCCCTCGTCTTTTACCAGCATAAGAGCATGAATGAGCCAAAACATGGCTT
GGCTCTTTGGGAAGCCAAAATGGCTGAAAAAGCCCGTGAGAAAGAGGAAGAGTGTGAAA
AGTATGGCCCAGACTATGTGCCTCAGAAATCCCATGGCAAAAAAGTGAAACGGGAGCCT
GCTGAGCCACATGAAACTTCAGAGCCCACTTACCTGCGTTTCATCAAGTCTCTTGCCGA
AAGGACCATGTCCGTGACCACAGACTCCACAGTAACTACATCTCCATATGCCTTCACTC
GGGTCACAGGGCCTTACAACAGATATATAGGTACCGGGTCGGGTAGTGGCTCTGGTAG
TGGTTCTGGTTCTATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGT
TCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAG
GGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAA
GGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCA
AGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAG
GGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCA
GGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACT
TCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAG
CGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAA
GGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGC
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AGCTGCCCGGCGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGAC
TACACCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGA
CGAGCTGTACAAGTAGGCGGCCGC 
 
